MoS unveils First TDB Window to fund High-Risk Technology Commercialisation (See 'Corp Brief') NMDC records Highest-Ever Production, Sales and Financial Performance (See 'Corp Brief') DoT is actively promoting digital safety and preventing telecom-related frauds: MoS (See 'Corp Brief') A & C - Referral court not required to conduct detailed or contested inquiry & must limit itself to ascertaining whether underlying contract contains an arbitration clause covering disputes between the parties: HC (See 'Legal Desk') IICA organises Training Program on Companies Act, Competition Law & IBC (See 'Corp Brief') DCPC organises Job Fair in collaboration with AIPMA (See 'Corp Brief') SEBI - If Noticee violated regulation 23(1) and 23(4) of LODR Regulations as alleged in SCN, Noticee is liable for payment of monetary penalty in terms of section 15HB of SEBI Act: SEBI (See 'Legal Desk') SAIL records highest-ever January '26 performance (See 'Corp Brief') Paradip Port Authority wins First Prize at Swachhata Pakhwada (See 'Corp Brief') Atal Innovation Mission hosts Flagship Conclave for National Incubation Ecosystem (See 'Corp Brief') Trade Marks - Procedural defects & inadvertent errors which are curable should not be permitted to defeat substantive rights, unless shown to be deliberate, mala fide, or prejudicial to opposite party: HC (See 'Legal Desk') CCI approves subscription to 15.01% equity of Ambit Wealth by Daiwa International (See 'Corp Brief') India, Bhutan to strengthen Cooperation in Power Sector (See 'Corp Brief') CCI okays AXDI LDII SPV to acquire shares of Aadhar Housing Finance (See 'Corp Brief') PMLA - Unless resolution is approved by NCLT, matter under PMLA for attachment of property may proceed even against corporate debtor: SAFEMA (See 'Legal Desk') SAIL, RITES sign MoU for diesel locomotive leasing and maintenance (See 'Corp Brief') Paswan calls for countering Misinformation on Processed Foods (See 'Corp Brief') Misc - If public authority holds any information in form of data, statistics, abstracts, etc. an applicant can have access to same under RTI Act subject to exemptions u/s 8: IBBI (See 'Legal Desk') Horticulture output reaches 367.72 million tonnes in 2024–25: Chouhan (See 'Corp Brief') SEBI - Contention of Noticees cannot be accepted as ground to seek exoneration qua their liability regarding failure to comply with regulatory limits: SEBI (See 'Legal Desk') HLC on banking to align financial sector growth to Viksit Bharat (See 'Corp Brief') Infra Risk Guarantee Fund to instil confidence in private developers (See 'Corp Brief') Shares buyback to be taxed as capital gains for all categories of shareholders (See 'Corp Brief') IIFT achieves 1st Position in Times B-School Ranking 2026 (See 'Corp Brief') Centre to enable States to establish regional medical hubs for tourism (See 'Corp Brief') Budget lays emphasis on scaling up manufacturing in 7 strategic sectors (See 'Corp Brief') Competition Act - intervention of CCI not warranted where allegations contained in Information are vague, sweeping & unsupported by material particulars necessary to establish contravention of Sections 3 or 4 of the Act: CCI (See 'Legal Desk') Interest accrued on motor accident compensation will no longer attract TDS (See 'Corp Brief') FM proposes uniform MAT Treatment for non-resident opting for Presumptive Tax (See 'Corp Brief') Tax certainty for non-resident individuals (See 'Corp Brief') Govt. revised criteria for Inter-Group loan exclusion from 'Dividend' definition (See 'Corp Brief') FDI Limit in Insurance Sector raised to 100%, subject to full domestic investment of premiums (See 'Corp Brief') Govt to facilitate ICAI, ICSI, ICMAI to run short-term know-how courses for youth (See 'Corp Brief') Government to set up 'BharatTradeNet' as Unified Digital Platform for international trade (See 'Corp Brief') Sovereign Gold Bond Capital Gains exemption to apply only to original holders at maturity (See 'Corp Brief') CSIR-NIO's Vizag Centre to play key role in offshore energy: MoS (See 'Corp Brief') FEMA - Statement recorded u/s 37 of FEMA did not amount to confession of criminal offence: HC (See 'Legal Desk') International Olympic Academy Director impressed by India's vision for sports (See 'Corp Brief') WB ranks India among top 5 in terms of private investment in infra (See 'Corp Brief') SEBI - In absence of explicit permission/exemption with respect to RFQ requirements, Noticee should have suspended its services if it was not feasible to engage large amounts of funds into working capital: SEBI (See 'Legal Desk') Survey: India should focus on application-based AI tools (See 'Corp Brief') IBC - NCLT can't decide title disputes over assets, including IPRs such as trademarks, unless they have direct & proximate nexus with insolvency resolution process: SC (See 'Legal Desk') UNCTAD ranks India as leading economy in trade partner diversification (See 'Corp Brief') The Securities Markets Code, 2025: Strengthened Enforcement, Weakened Accountability? (See 'CORP EINSICHT')

Print

CCI okays internal acquisition by Glaxo Smith Kline

Published: Jan 24, 2022

By TIOLCorplaws News Service

NEW DELHI, JAN 24, 2022: THE Competition Commission of India (CCI) approves acquisition by GlaxoSmithKline Consumer Healthcare Overseas Limited and GlaxoSmithKline Consumer Healthcare UK Trading Limited (Acquirers) of shareholding in GlaxoSmithKline Asia Private Limited (Target) under Section 31(1) of the Competition Act, 2002.

The Proposed Combination involves collective acquisition of 100% shares of the Target by the Acquirers. Further, prior to the proposed combination, GSKAPL will acquire the trademarks pertaining to "Iodex" and "Ostocalcium" brands in India alongwith the legal, economic, commercial and marketing rights of such brands and other associated assets (GSK Consumer Brands) from GlaxoSmithKline Pharmaceuticals Limited.

GlaxoSmithKline Consumer Healthcare Overseas Limited is a wholly-owned subsidiary of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited ("GSK CH HoldCo"). It is a part of the overall GlaxoSmithkline (GSK) group and its principal activity is to act as an investment holding company for GSK CH HoldCo and its subsidiaries.

GlaxoSmithKline Consumer Healthcare UK Trading Limited is a part of the overall GSK group and is a wholly-owned subsidiary of GSK CH HoldCo. It is engaged in the distribution and sale of consumer healthcare products, manufacturing, marketing, providing management services to the consumer healthcare group and providing research and development services to other consumer healthcare companies within the GSK group.

GSKAPL is a consumer healthcare company that is engaged in the marketing and distribution of oral healthcare products under various brand names such as Sensodyne, Parodontax, Polident and over-the-counter medicines products under the brand names such as Crocin, ENO. 

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.